Rivaroxaban
Signals from filings dated June 2025 – October 2026 · Last checked 7 Nov 2026
Supply outlook
↑ GROWINGFour Indian plants have filed to make rivaroxaban. The largest is Fusion Health Care, which adds it at 200 kg/day to an approved API unit near Kamareddy, Telangana. Besi (Nashik) and Juvenus (Tamil Nadu) are small lines, and a new unit near Ahmedabad lists it in a 36 t/yr group shared with 16 other APIs. None of these filings is a clearance for rivaroxaban yet. Nothing in the filings we track shows a plant leaving the molecule.
Signals
Nanoarray Biosciences Pvt. Ltd.
Plot 46-47, Suvas Global Industrial Hub, Moraiya, Sanand, Ahmedabad, Gujarat
- ✓ Terms of reference
- ✓ Public hearing · 30 Oct 2026
- Next: clearance
- Consent to operate
- DMF / CEP
Listed in Group E (17 products, and/or): 36 t/yr shared across the group. Greenfield API unit, 283.2 t/yr in total. Public hearing held 30 Oct 2026. Source: EIA executive summary, GPCB
Besi Drugs Pvt. Ltd.
Gat No. 200/1, Lakhmapur, Dindori, Nashik, Maharashtra
- ✓ Terms of reference
- ✓ Public hearing · 22 Apr 2026
- Next: clearance
- Consent to operate
- DMF / CEP
Expansion of an API and intermediates unit from 546 to 600 t/yr; the same filing adds sitagliptin, linagliptin, aprepitant and mirabegron. Source: EIA executive summary, MPCB
Fusion Health Care Pvt. Ltd.
Sy. No. 667, Bhiknoor, Kamareddy, Telangana
- ✓ Terms of reference
- ✓ Public hearing · 7 Jan 2026
- Next: clearance
- Consent to operate
- DMF / CEP
New product at the site, 200 kg/day. Expansion of an approved API unit still under construction (EC 2021; taken over by Fusion Health Care in 2023). Worst case 6 products run at once; site total 1,000 to 2,420 kg/day. Public hearing held 7 Jan 2026. Source: EIA executive summary, TGPCB
Juvenus Drugs
Plot 38, TANSIDCO Industrial Estate, Tindivanam, Villupuram, Tamil Nadu
- ✓ Terms of reference · 16 Jun 2025
- Next: public hearing
- Clearance
- Consent to operate
- DMF / CEP
Greenfield unit, 187.9 t/yr across 19 products; rivaroxaban is a niche line here. Source: Draft EIA executive summary, TNPCB
How to read this
Three of the four filings are small or shared lines. Fusion is different: 200 kg/day is a commercial-scale line, but the site runs up to six products at a time, so rivaroxaban will get campaigns, not a dedicated train. If you buy rivaroxaban, Fusion is the name to watch once its expansion is cleared and a DMF or CEP appears.
Who makes Rivaroxaban today: 118 listings
Current manufacturers with US DMF and CEP status, plant addresses and contacts.
| Manufacturer | Country | US DMF | CEP | Contact |
|---|---|---|---|---|
| Bayer AG | Germany | ✓ | — | In database |
| Tecoland Corp. | United States | — | — | In database |
| MegaFine Pharma Pvt Ltd | India | — | — | In database |
| + 115 more listings in api-fdf.com → | ||||
Three examples from the api-fdf.com database, refreshed weekly. Plant addresses and contacts are shown in the database.
Follow Rivaroxaban
Get an email when a new filing adds, cuts or moves this molecule to the next stage.